Summary of Key Points Core Viewpoint - The announcement details the pledge of shares by a major shareholder of Shaanxi Kanghui Pharmaceutical Co., Ltd., indicating a financial maneuver that does not significantly alter the company's equity structure or pose substantial repayment risks. Group 1: Shareholder Information - Shaanxi Kanghui Pharmaceutical's major shareholder, Yangzhou Chuangxiang Investment Partnership (Limited Partnership), holds 5,992,800 shares, representing 6% of the company's total equity [1]. - Chuangxiang Investment has pledged 1,997,600 shares, which accounts for 33.33% of its holdings and 2% of the total shares of the company [1]. Group 2: Pledge Details - The pledge registration date is set for July 2, 2025, with the maturity date on June 22, 2026 [1]. - The pledged shares do not involve significant asset restructuring or performance compensation guarantees [1]. Group 3: Financial Stability - Chuangxiang Investment is reported to have a good credit status and repayment capability, indicating no substantial repayment risk that could lead to significant changes in the company's equity structure [3].

Market Performance - The hair medical concept sector rose by 2.34%, ranking 10th among concept sectors, with 19 stocks increasing in value, including JiuZhiTang which hit the daily limit, and TianEnKang, KangHui Pharmaceutical, and KangYuan Pharmaceutical which rose by 6.42%, 5.16%, and 4.55% respectively [1] - The top gainers in today's market include the fruit index at 4.73%, PCB concept at 3.27%, and AI mobile at 2.92%, while the military restructuring concept saw a decline of 1.49% [1] Capital Flow - The hair medical concept sector experienced a net inflow of 219 million yuan, with 11 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 10 million yuan. JiuZhiTang led with a net inflow of 172 million yuan, followed by ShuiYang Co., KangYuan Pharmaceutical, and NengTe Technology with net inflows of 34.25 million yuan, 21.05 million yuan, and 13.44 million yuan respectively [1] - In terms of capital inflow ratios, JiuZhiTang, ShuiYang Co., and KangHui Pharmaceutical had the highest net inflow rates at 33.17%, 6.81%, and 6.15% respectively [2] Stock Performance - JiuZhiTang saw a significant increase of 10.06% with a turnover rate of 7.62%, while ShuiYang Co. and KangYuan Pharmaceutical increased by 3.12% and 4.55% respectively [2] - Stocks such as *ST JinBi and AoYang Health experienced declines of 0.69% and 0.26% respectively, indicating some volatility within the sector [1][3]

Company Overview - Kanghui Pharmaceutical was established on December 24, 2009, with a registered capital of 99.88 million RMB, and is located in Xi'an, Shaanxi Province [3] - The company specializes in the research, development, production, and sales of traditional Chinese medicine [3] - The current chairman is Wang Yanling, and the company has 906 employees [3] Shareholder and Pledge Information - A major shareholder, Yangzhou Chuangxiang Investment Partnership, holds 5,992,800 shares, accounting for 6% of the total share capital [3] - The shareholder pledged 1,997,600 shares, which is 33.33% of their holdings and 2% of the total share capital, for financing to supplement liquidity [3] - The pledge registration was completed on July 2, 2025, with a maturity date of June 22, 2026, and the creditor is Yang Yin [3] Financial Performance - The company's revenue for 2022, 2023, and 2024 is projected to be 492 million RMB, 673 million RMB, and 562 million RMB, reflecting year-on-year growth rates of 11.01%, 36.92%, and a decline of 16.54% respectively [4] - The net profit attributable to shareholders for the same years is projected to be -63.06 million RMB, -26.16 million RMB, and -89.63 million RMB, with year-on-year changes of -272.84%, 58.52%, and -242.62% respectively [4] - The company's asset-liability ratios for the same years are 43.68%, 50.29%, and 51.96% [4] Risk Assessment - The company has a total of 99 risk alerts recorded in Tianyancha, with 159 surrounding risks, 4 historical risks, and 228 warning alerts [4]

证券代码：603139 证券简称：康惠制药 公告编号：2025-038 陕西康惠制药股份有限公司 关于持股 5%以上股东部分股权质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 陕西康惠制药股份有限公司（以下简称"公司"）持股 5%以上股东扬州 创响投资合伙企业（有限合伙）（以下简称"创响投资"）持有公司股份5,992,800 股，占公司总股本的 6%。 创响投资本次质押公司股份1,997,600股，占其持有公司股份的33.33%， 占公司总股本的 2%。 一、本次股份质押基本情况 本次质押登记手续已在中国证券登记结算有限责任公司办理完成；本次质 押股份不涉及重大资产重组业绩补偿等事项的担保和其他保障用途。 二、股东累计质押情况 | | | | | | | | 已质押 | | | 未质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质 | | 占其 | 占公 | | 股份情况 | | 股 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-037 陕西康惠制药股份有限公司 关于为春盛药业在金都村镇银行的借款 提供反担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 反担保对象：都江堰市产权流转融资担保有限责任公司 同》，为春盛药业在金都村镇银行申请的 400 万元贷款向都江堰市产权流转融资 担保有限责任公司提供保证反担保，反担保方式为连带责任保证。反担保保证期 间为都江堰市产权流转融资担保有限责任公司代春盛药业偿还全部借款或部分 借款本金、利息（包括复利和罚息）及其他费用之日起五年。 同时，春盛药业董事长骆春明先生及其一致行动人尹念娟女士与公司签署 《反担保合同》，以连带责任保证的方式在《保证反担保合同》中约定的都江堰 市产权流转融资担保有限责任公司代春盛药业偿还的资金总额和资金占用费的 49%范围内向公司承担反担保责任，即反担保金额为人民币壹佰玖拾陆万元整， 保证期间与都江堰市产权流转融资担保有限责任公司提供的担保期限一致。 本次反担保前，公司为都江堰市产权流转融资担保 ...

Core Viewpoint - The announcement details a significant change in control for Xi'an Kanghui Pharmaceutical Co., Ltd., as its controlling shareholder, Kanghui Holdings, plans to transfer 22% of its shares to Jiaxing Yuehe Zhichuang Technology Partnership, resulting in a new controlling entity and actual controllers [2][3]. Group 1: Equity Change Overview - Kanghui Holdings intends to transfer 21,973,600 shares, representing 22% of the total shares of the listed company, to Yuehe Zhichuang at a price of RMB 24.70 per share [2]. - Following the completion of this share transfer, the controlling shareholder will change to Yuehe Zhichuang, with the actual controllers being Li Hongming and Wang Xuefang [2]. Group 2: Progress of Equity Change - The equity change has passed compliance review by the Shanghai Stock Exchange [3]. - The final implementation of the share transfer is subject to the completion of share transfer registration procedures at the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, indicating some uncertainty in the final outcome [3].

证券代码：603139 证券简称：康惠制药 公告编号：2025-036 陕西康惠制药股份有限公司 审核暨控制权拟发生变更的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 本次权益变动相关事项已通过上海证券交易所合规性审核。 本次权益变动事项尚需在中国证券登记结算有限责任公司上海分公司办 理股份过户登记手续，最终实施结果尚存在不确定性，敬请投资者注意投资风险。 一、本次权益变动基本情况 2025 年 3 月 20 日, 陕西康惠制药股份有限公司（以下简称"康惠制药"、"上 市公司"）控股股东陕西康惠控股有限公司（以下简称"康惠控股"）与嘉兴悦合 智创科技合伙企业（有限合伙）（以下简称"悦合智创"）签署《股份转让协议》, 康惠控股拟向悦合智创协议转让其持有上市公司 21,973,600 股股份（占上市公 司股份总数的 22%），转让价格为人民币 24.70 元/股。2025 年 3 月 25 日，康惠 控股与悦合智创签署《股份转让协议之补充协议》，同时康惠控股出具《关于放 弃表决权的承诺函》，承诺自《股份转 ...

Core Points - The controlling shareholder of Kanghui Pharmaceutical (603139) is transferring 21,973,600 shares, representing 22% of the total shares, to Jiaxing Yuehe Zhichuang Technology Partnership at a price of RMB 24.7 per share [1] - Following the share transfer, the controlling shareholder will change to Yuehe Zhichuang, with the actual controllers being Li Hongming and Wang Xuefang [1] - Kanghui Pharmaceutical has received confirmation from the Shanghai Stock Exchange regarding the share transfer agreement, but the final implementation is subject to registration with the China Securities Depository and Clearing Corporation [1]

Summary of Key Points Core Viewpoint - The company has provided a guarantee of 6 million RMB for its subsidiary, Sichuan Pufengtang Pharmaceutical Co., Ltd, to secure a loan from China Bank, with a total guarantee balance of 10.97 million RMB remaining [1][2][3]. Group 1: Guarantee Details - The guarantee amount provided by the company is 6 million RMB, with a total guarantee balance of 10.97 million RMB after this transaction [1][3]. - The company has a counter-guarantee agreement with other shareholders of Pufengtang, covering 49% of the guaranteed debt [3][6]. - The guarantee is structured as a joint liability guarantee, covering principal, interest, penalties, and other related costs [5][6]. Group 2: Financial Status of the Guaranteed Entity - Sichuan Pufengtang has total assets of approximately 42.28 million RMB and total liabilities of about 45.54 million RMB, resulting in a negative net asset of approximately -3.25 million RMB [4][5]. - The company's revenue for the last fiscal year was approximately 2.28 million RMB, with a net loss of about -1.70 million RMB [5]. Group 3: Board's Opinion and Justification - The board of directors believes that the guarantee is necessary for the subsidiary's financing needs and aligns with the company's strategic interests, posing no adverse effects on the company's operations [6][7]. - The board approved the guarantee with unanimous support, indicating confidence in the subsidiary's financial management and risk control [7][8].

证券代码：603139 证券简称：康惠制药 公告编号：2025-035 陕西康惠制药股份有限公司 关于为菩丰堂提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 被担保人名称：四川菩丰堂药业有限公司（以下简称"菩丰堂"，系公 司控股子公司四川春盛药业集团股份有限公司的全资子公司） 本次担保金额：600 万元人民币；本次担保后实际为其提供的担保余额： 1,097 万元 特别风险提示：被担保人菩丰堂药业的资产负债率超过 70%，请广大投 资者充分关注担保风险。 一、担保情况概述 陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日及 2025 年 5 月 20 日，召开第五届董事会第十七次会议、第五届监事会第十四次会议及 2024 年年度股东大会，审议通过《关于 2025 年度预计为控股子公司提供担保的 议案》，同意公司为控股子公司在金融机构申请的综合授信额度提供不超过 19,800 万元的连带责任保证，其中，同意为菩丰堂在金融机构申请的授信，提 供不超过 1,100 万元 ...